Oncolytic virotherapy.

By D. Cervantes-García, R. Ortíz-López, N. Mayek-Pérez, A. Rojas-Martínez. Annals of Hepatology, 2008

799 citations recorded by the source corpus.

Current oncolytic virotherapy strategies are based in the accumulated understanding of the common molecular mechanisms displayed during cell transformation and viral infection, like cell cycle and apoptosis deregulations. Oncolytic virotherapy aims to achieve a strong cytolytic effect, highly restricted to transformed cells. Here, we describe the oncolytic virotherapy defined as the use of viruses like antitumor agents (wild and gene-modified oncolytic viruses) and the developed strategies to increase antitumor efficacy and safety. In addition, we discuss the advances and challenges concerning the use virotherapy in animal models and clinical trials. Some clinical trials of virotherapy have demonstrated promising results, particularly when combined with standard antineoplastic therapies. These preliminary accomplishments are opening the field for more research in several aspects, like vector modifications, pharmacodynamics, biosafety, new clinical applications, etc.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/29f60383c423fc1ca7cc088a673b5e1c8ffb3f70

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Jacques Banchereau
2. K. Palucka
3. B. Ruffell

In Oncology

1. K. Palucka
2. Jacques Banchereau
3. B. Ruffell

Citations in the corpus

• Dendritic Cells and Cancer Immunity (2016, background): “Building off of this concept has included the addition of stimulating agents such as cyclic dinucleotides to activate STING [74], or alternative delivery vehicles for GM-CSF such as oncolytic viruses [75].”
• The role of necroptosis in cancer biology and therapy (2019, background): “DAMP, and PAMP, which may activate dendritic cells and incur adaptive antitumor immunity [124, 147].”
• Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “These can be modified to express GM-CSF to attract DCs and lymphocytes at the lysed tumor site (Russell et al., 2012).”